There was one problem. The technology did not work. Not marginally. Not “promising but early.” It did not work at all. Behind the gleaming Palo Alto offices, the black-turtleneck uniform Holmes had adopted as deliberate homage to Jobs, and the wall of press coverage celebrating the revolution she was leading, Theranos was running its proprietary analyzer on only a small fraction of the tests it sold to customers. The rest were run on conventional third-party analyzers from Siemens — the same machines available to any lab — while patients and ordering physicians received results with no indication the tests hadn’t been run on the Theranos device. And when the proprietary analyzer was used, its results were frequently inaccurate to a degree that posed genuine medical risk.
Bad Blood, published in 2018 by Wall Street Journal reporter John Carreyrou, is the definitive account of how one of the most spectacular frauds in Silicon Valley history unfolded — and why it took so long for anyone to stop it. Carreyrou broke the original Theranos story in 2015 after months of reporting against intense legal pressure from the company. The book expands that reporting into a granular narrative of creation, deception, and collapse that reads like a thriller while functioning as a serious investigation into the psychology of fraud, the failures of Silicon Valley’s anti-regulatory culture, and the particular vulnerability of powerful men to charismatic founders with compelling stories.
Plain Truth on Bad Blood
Bad Blood is one of the best pieces of investigative journalism turned into a book in recent memory. Carreyrou’s reporting is meticulous, his sourcing extensive, his prose clear and propulsive without being sensationalized. The narrative rests on interviews with dozens of former Theranos employees who risked significant legal and financial consequences to speak — and whose courage in doing so makes both the book and the eventual criminal prosecution possible.
The book’s value extends well beyond the specific story of Theranos. It’s a case study in how fraud scales in environments that reward confidence over competence, how charisma can substitute for evidence across surprisingly long stretches of time, and how the culture of Silicon Valley — which valorizes the visionary who sees what others cannot and dismisses skeptics as people who lack the imagination to understand the future — creates the structural conditions in which fraud can flourish and hide.
The limitation: Carreyrou is a journalist, not a psychologist or a business school professor, and he doesn’t attempt to build a systematic framework from the Theranos story. The lessons are embedded in the narrative rather than extracted and organized. Readers looking for explicit takeaways will need to do that work themselves. But the narrative itself is so richly detailed that the patterns emerge clearly enough anyway.
The verdict: essential reading for anyone in business, investing, healthcare, or any field where high-stakes decisions get made on claimed capabilities that can’t be fully verified. The story of Theranos is not a story about one uniquely evil person. It’s a story about the conditions under which fraud becomes possible, and the systems that should have stopped it but didn’t.
Elizabeth Holmes and the Architecture of Deception
Understanding how Theranos sustained its fraud for more than a decade requires understanding Holmes as Carreyrou documents her — not as a cartoon villain but as a specific type of person whose psychology made her exceptionally dangerous in the particular environment she occupied.
Holmes possessed several traits that combined in a way that was difficult to resist. She was physically striking in a manner she cultivated deliberately — the voice deepened to add authority, the wardrobe engineered to signal seriousness and vision, the eye contact maintained at an intensity many interviewees describe as almost unsettling. She had genuine charisma: the ability to make each person she spoke with feel she was focused entirely on them, that their specific concerns were the ones that mattered most to her. And she had a story — the death of an uncle from cancer, the terror of needles, the conviction she could build something that would save lives — emotionally resonant enough to make skepticism feel callous.
Critically, she operated in an environment optimized for exactly the kind of confidence she projected. Silicon Valley’s cultural DNA includes the conviction that transformative technology always looks impossible to skeptics, that the people who say it can’t be done are simply not visionary enough, and that regulatory and scientific skepticism are obstacles to be routed around rather than validations to be sought. When investors, board members, and potential partners raised technical questions about whether the Theranos technology could do what Holmes claimed, the cultural framework they were operating in told them that their inability to understand the technology was the problem, not the technology’s actual limitations.
This cultural framework was not incidental to the fraud — it was structural to it. Holmes understood, consciously or not, that the Silicon Valley ecosystem would punish doubt far more than it would punish confident assertion. She leaned into that asymmetry with extraordinary discipline.
The Technology That Never Worked
The central claim of Theranos — that a device called the Edison could run hundreds of laboratory tests accurately from a tiny finger-prick blood sample — was not merely premature or optimistic. It contradicted basic principles of biochemistry and physics the company’s own scientists understood from the beginning.
The fundamental problem: finger-prick blood has different properties than venous blood drawn from a vein. More susceptible to contamination, harder to process consistently, and available in tiny volumes that create serious accuracy constraints for many assays. The analytical sensitivity required to produce reliable results from such small samples — particularly for tests requiring detection of very small quantities of a biomarker — is orders of magnitude greater than what the Edison could deliver. As Theranos’s own laboratory director eventually testified, the device was essentially a glorified cartridge reader that could handle a handful of tests acceptably; the hundreds of tests the company marketed were simply run on conventional analyzers in the same lab.
The scientists and engineers who worked at Theranos knew this. Carreyrou documents a parade of talented researchers who joined the company excited by its mission, discovered the technology didn’t work, raised concerns internally, and were fired, marginalized, or threatened with legal action when their concerns weren’t welcomed. The scientific staff was not stupid or complicit — people operating in an environment where raising technical objections was treated as a form of disloyalty, and where the cultural and legal pressure to stay silent was enormous.
Holmes and her partner Sunny Balwani — the company’s President and COO, and Holmes’s secret romantic partner — responded to internal technical challenges not by adjusting the claims or the timeline but by asserting the scientists raising them lacked the vision to understand what was possible. Here’s the moment confidence stops being an asset and becomes a danger: when the person in charge no longer distinguishes between “our team says it can’t be done and they’re wrong” and “our team says it can’t be done because physics says it can’t be done.” Holmes appears to have been incapable of making that distinction, or to have chosen not to make it.
The Board That Failed to Ask
The Theranos board is one of the most remarkable documents of institutional failure in recent American business history. At various points it included George Shultz (former Secretary of State), Henry Kissinger, James Mattis (before his appointment as Secretary of Defense), William Perry (former Secretary of Defense), and two former senators. An extraordinary collection of distinguished public servants, as Carreyrou observes, and none of them had any medical or biotechnology expertise.
Not an accident. Holmes built a board of prestigious validators who would provide credibility and connections rather than technical scrutiny. The former secretaries of state and defense gave Theranos the kind of reputational endorsement that opened doors to government contracts and military partnerships. They weren’t there to evaluate whether the technology worked. They were there to signal, by their presence, that the technology was serious and trustworthy.
The absence of anyone on the board with the knowledge to evaluate the core technology claim is the most damning institutional failure in the Theranos story. A board of directors has a fiduciary responsibility to exercise oversight. That responsibility cannot be discharged by people who lack the basic knowledge to ask the right questions. The Theranos board was not negligent because its members were unintelligent — they were, by any measure, accomplished people. It was negligent because Holmes had deliberately assembled a board that would not, and could not, provide the specific oversight her company required.
George Shultz’s role is particularly painful because Carreyrou documents it in granular detail. Shultz’s grandson Tyler worked at Theranos and became one of the early whistleblowers. He told his grandfather directly the company was misleading patients and investors. Shultz refused to believe him, sided with Holmes, and reportedly stopped speaking to his grandson for a period. The gravitational pull of Elizabeth Holmes’s narrative was strong enough to override a grandfather’s trust in his own family.
The Culture of Fear Inside Theranos
The internal culture Carreyrou documents at Theranos is recognizable to anyone who has studied how fraudulent organizations sustain themselves: a combination of inspiration and terror that makes truthful internal communication essentially impossible.
Holmes was genuinely inspiring to many who joined Theranos early. The mission — democratizing healthcare, catching disease early, saving lives through accessible testing — was real and important. Many of the scientists and engineers who joined were motivated by genuine belief in the possibility of what they were trying to build. That genuine motivation was an asset Holmes could draw on even as the technical picture became increasingly clear.
But alongside the inspiration was Sunny Balwani, who ran the day-to-day operations of the company with a management style multiple former employees describe as abusive. Balwani monitored employee badge swipes to track when people arrived and left. He conducted aggressive interrogations of employees who raised questions. He presided over a culture in which internal criticism of the technology or the business practices was treated as a form of betrayal, and in which the consequences of perceived disloyalty — firing, legal threats, public humiliation — were severe enough that most employees chose silence.
Theranos’s legal operation was deployed aggressively against anyone who attempted to speak about the company’s problems. Former employees were bound by non-disclosure agreements so comprehensive that many felt they couldn’t discuss their Theranos experience even with lawyers they’d consulted about their own legal exposure. David Boies, the prominent attorney whose firm Boies Schiller was retained by Theranos, sent letters to reporters, sources, and even family members of employees suggesting legal consequences would follow from any disclosure. This legal pressure was enormously effective in slowing reporting and preventing the kind of coordinated whistleblowing that might have exposed the fraud years earlier.
The Patients Who Were Harmed
The element that elevates the Theranos story from financial fraud to something more serious is that real patients received inaccurate medical results that affected their care. This is the dimension both the press coverage and the eventual criminal prosecution had to grapple with — and that makes Bad Blood something more than a story about investor losses.
Theranos operated patient-facing testing through a partnership with Walgreens that placed Theranos Wellness Centers in Walgreens stores across Arizona and California. Real patients paid real money for blood tests, received results back, and made medical decisions based on those results. When the results were inaccurate — and they frequently were — the consequences were not abstract. Patients were told their cancer markers were elevated when they weren’t. Patients were told their HIV tests were positive when they were negative. Patients who made decisions about medication dosages, further testing, or treatment plans based on Theranos results were making those decisions based on data the company knew was unreliable.
Carreyrou documents specific cases: a woman who received an alarming false positive for HIV who spent weeks in terror before a retest with a different lab showed the Theranos result was wrong. Patients whose medication management for serious conditions was complicated by inaccurate Theranos panels. Physicians who trusted the results their patients brought in and made clinical decisions accordingly.
This dimension of the story is why the criminal prosecution ultimately succeeded. Federal prosecutors were able to demonstrate not just securities fraud — investors deceived about the company’s capabilities — but wire fraud in which patients were directly harmed. Holmes was convicted of fraud against investors. The trial demonstrated that the harm from Theranos wasn’t confined to the wealthy investors who lost money, but extended to the ordinary patients who were supposed to benefit from the revolution she claimed to be leading.
The Whistleblowers and the Press
One of the most instructive dimensions of Bad Blood is its account of how the story finally broke — and the significant structural obstacles that had to be overcome before it could.
Multiple Theranos employees raised concerns internally before going outside the company. Tyler Shultz and Erika Cheung are the two most prominent whistleblowers Carreyrou documents, and both of their stories involve extended periods of internal escalation, legal threats after they left the company, and significant personal cost before their information contributed to the eventual investigation. Neither went to the press directly — their information reached Carreyrou through a chain of sources and intermediaries he carefully reconstructed.
The Centers for Medicare and Medicaid Services (CMS) conducted an inspection of Theranos’s Newark, California laboratory in 2015 and found deficiencies so serious it threatened to revoke the lab’s certification and bar Holmes from operating a clinical laboratory for two years. This regulatory action — not journalistic investigation, not investor concern, not internal whistleblowing — was ultimately the proximate cause of the company’s collapse. The regulatory infrastructure, when it finally functioned, worked.
The delay in regulatory action is itself an important lesson. Theranos had managed to operate in a regulatory gray area for years, using legal structures and political connections to avoid the direct FDA oversight its technology should have attracted. The company had classified its tests as “laboratory developed tests” — a category subject to lighter oversight — rather than as the novel medical devices the underlying technology actually represented. This classification decision, made deliberately to avoid regulatory scrutiny, was perhaps the single most consequential legal choice the company made.
What Silicon Valley’s Culture Got Wrong
The Theranos story is sometimes treated as an anomaly — the story of a uniquely sociopathic founder and her uniquely credulous investors. Carreyrou is too good a journalist to accept that framing, and the book makes clear the conditions that allowed Theranos to flourish were not unique to Theranos.
Silicon Valley’s culture of “fake it till you make it” — the normalization of projecting confidence about capabilities that don’t yet exist as a necessary component of fundraising and team-building — creates a structural tolerance for the kind of misrepresentation Theranos eventually took to criminal extremes. The difference between “we have a product that works exactly like I described” and “we have a vision for a product we believe will work like this” is not always clearly drawn, and the culture rewards founders who blur that line.
The disregard for regulatory infrastructure is equally problematic. The regulatory frameworks that govern medical devices, food safety, drug approval, and clinical laboratory testing exist because unregulated deployment of these products in the past caused serious harm. Imperfect, often slow, frequently frustrating to innovators who know their products are safe. But the Theranos story is a precise illustration of what happens when those frameworks are actively avoided in a domain — clinical diagnostics — where patient safety depends on them.
Holmes internalized Silicon Valley’s genuine insight — that regulation can be an obstacle to beneficial innovation — and weaponized it as a shield against oversight that existed for good reasons. Not a story about one person’s character defect. A story about a cultural framework that created the conditions for that weaponization.
The Criminal Trial and Its Outcome
Holmes was charged by federal prosecutors in 2018 with wire fraud and conspiracy to commit wire fraud. The trial, conducted in 2021, resulted in her conviction on four of eleven counts — specifically, the counts related to defrauding investors rather than the counts related to defrauding patients. She was sentenced to eleven years and three months in federal prison in November 2022.
Balwani was tried separately and convicted on all twelve counts against him, including fraud against patients, and sentenced to nearly thirteen years. The divergent outcomes reflected both the different roles the two played — Balwani ran day-to-day operations and is more directly implicated in the patient-level decisions — and the different defense strategies employed at trial.
Holmes’s trial defense included the claim that she herself had been deceived — that Balwani had been emotionally and psychologically abusive throughout their relationship, that she’d operated under his influence, and that she genuinely believed in the technology she was selling. The jury didn’t fully accept this defense on the patient fraud counts but found it sufficient to produce reasonable doubt on some investor fraud counts.
The criminal outcomes matter because they establish, at legal fact, that Theranos was not a case of visionary overreach or premature confidence. It was fraud — the deliberate misrepresentation of facts known to be false to people who relied on those facts. That legal clarity matters both for the specific individuals harmed and for the more general question of where the line falls between acceptable startup narrative and criminal deception.
What Resilient Leaders Take From This Story
Bad Blood is not a book about weakness. Holmes was not weak. She was disciplined, intelligent, relentless, and extraordinarily persuasive. The failure Carreyrou documents was not a failure of will or energy. It was a failure of the specific trait separating sustainable high performance from spectacular collapse: the willingness to be honestly accountable to reality.
The leaders and organizations that endure are those that have built systems for honest information to reach decision-makers — including information that contradicts what the decision-makers want to believe. The Theranos story is a case study in the destruction of those systems: the firing of scientists who reported negative results, the legal suppression of whistleblowers, the construction of a board that couldn’t ask technical questions, the cultural framework that treated doubt as disloyalty.
Resilience in the face of adversity requires the ability to distinguish between adversity that comes from external forces and adversity that comes from the unwillingness to see reality clearly. Holmes faced both: genuine technical challenges that may have been insurmountable, and the compounding adversity she created by refusing to acknowledge them. The first was a problem. The second was a choice.
For anyone building anything — a company, a team, a career — the Theranos story is a useful test: are the people around you able to bring you bad news? Do you punish the bearers of unwelcome information, or reward them for honesty that’s costly to deliver? The answers predict the long-term trajectory of any organization more reliably than the confidence of its leader or the elegance of its pitch deck.
The most important sentence in the book may be the simplest one. When Tyler Shultz finally mustered the courage to tell his grandfather that Theranos was deceiving patients and investors, and his grandfather chose not to believe him, he was witnessing something universal: the way a sufficiently compelling story, backed by sufficiently powerful social pressure, can override even the direct testimony of someone we trust. Every organization has a version of this dynamic. The question is whether its culture rewards the people who tell the hard truth anyway.
Key Lessons From Bad Blood
-
Charisma is not a substitute for competence in technical domains. The ability to inspire investors and board members is not evidence that the underlying technology works. In high-stakes technical domains — medicine, aviation, infrastructure — the validation of independent experts matters more than the persuasiveness of the founder.
-
Culture of fear destroys the feedback loops organizations need to survive. When the people closest to the work cannot deliver accurate information upward without fear of consequences, the organization loses its most important error-correction mechanism.
-
Regulatory frameworks in safety-critical domains exist for reasons that matter. The instinct to route around regulation as an obstacle to innovation is often correct in low-stakes domains. It is dangerous in domains where the regulation exists because unregulated deployment caused serious harm to people who trusted the product.
-
Board composition determines the questions that get asked. A board assembled for prestige and connections rather than relevant expertise cannot provide the oversight function boards exist to provide. The Theranos board is the definitive argument for why technical domains require board members with technical knowledge.
-
The gap between “vision” and “fraud” is crossed when you know the difference and choose not to disclose it. Every startup projects forward confidence. The criminal threshold is not the projection — it is the deliberate concealment of known facts that would change how investors and customers evaluate the claims.
The Psychological Portrait of a True Believer
One of the central debates about Elizabeth Holmes — a debate that ran through the criminal trial and continues in the broader cultural conversation about Theranos — is whether she was a deliberate fraudster from the beginning or a true believer who crossed into fraud gradually, driven by the escalating commitment of a founder who’d raised too much money and attracted too many believers to admit the technology wasn’t going to work on the timeline she’d promised.
Carreyrou does not fully resolve this question, in part because the evidence does not fully resolve it. What the reporting does establish is that the pattern of deception — the deliberate concealment of the fact that patient tests were being run on non-Theranos equipment, the false representations to investors about the technology’s capabilities, the legal suppression of whistleblowers — began early and was systematic. Whatever Holmes believed about the ultimate promise of the technology, she was making representations she knew to be false about its current state.
The psychological complexity is this: it is entirely possible to genuinely believe in the long-term promise of a technology while deliberately misrepresenting its current capabilities. The founder who says “we will achieve this” and the founder who says “we have achieved this” are making different claims, and the gap between them is not merely semantic — it’s the gap between a pitch and a fraud. Holmes made the second claim repeatedly and specifically, to investors who were making decisions based on it and to patients who were receiving medical care based on it.
The trial testimony of former employees suggested Holmes was capable of extraordinary compartmentalization — of maintaining the external performance of a visionary founder while operating internally in ways she must have known were inconsistent with the claims she was making. Not unique to Holmes; a psychological mechanism appearing in many accounts of fraud. But it requires a particular kind of self-deception that’s more frightening than simple cynical dishonesty, because the person practicing it is genuinely persuaded, at some level, that the deception is justified by the larger truth they believe they’re serving.
“The minute you have a backup plan, you’ve admitted you’re not going to succeed.” — Elizabeth Holmes (on her conviction that Theranos would succeed)
The Regulatory and Legal System That Eventually Worked
One of the most instructive aspects of the Theranos story is the account of how the regulatory and legal mechanisms that eventually stopped the fraud actually functioned — and the significant obstacles those mechanisms faced before they succeeded. Not simply a story about regulatory failure. Also a story about regulatory resilience under serious pressure.
The Centers for Medicare and Medicaid Services laboratory inspection that identified deficiencies in Theranos’s Newark lab in 2015 was the proximate trigger for the company’s collapse. That inspection was triggered not by any deliberate regulatory action targeting Theranos specifically, but by the routine inspection cycle that applies to all clinical laboratories certified to receive Medicare and Medicaid reimbursement. The system that eventually caught Theranos was not a targeted investigation. It was a routine process functioning as designed.
A meaningful observation about the value of regulatory infrastructure that operates continuously rather than only in response to specific complaints. Theranos had managed to avoid focused regulatory attention for years through a combination of legal structuring (classifying its tests as laboratory developed tests rather than regulated medical devices) and political connections. The routine inspection process bypassed those defenses precisely because it wasn’t responsive to the company’s specific legal strategies.
The Securities and Exchange Commission investigation and the Department of Justice criminal prosecution that followed the CMS findings demonstrated that the criminal justice system, when given a clear evidentiary record, was capable of prosecuting a high-profile fraud case effectively. Holmes and Balwani were charged, tried, convicted, and sentenced — outcomes by no means guaranteed in complex financial fraud cases, where the legal complexity of the transactions and the resources of the defendants can make prosecution difficult and conviction uncertain.
The timeline of the legal process was slow — approximately seven years elapsed between Carreyrou’s first contact with whistleblowers and the sentencing of Holmes. But the process functioned. The lesson is not that the regulatory and legal systems worked perfectly, but that they worked — after significant delay and against significant resistance — in ways that produced accountability for one of the most public frauds of the twenty-first century.
What Bad Blood Teaches About Building Trust
Trust, in organizations and in relationships, is built through the consistent alignment of what you say and what you do over time. It’s a stock that accumulates slowly through repeated demonstration of alignment and depletes rapidly through single acts of misalignment. The Theranos story is a case study in the rapid depletion of an enormous trust stock Holmes had built through years of careful performance — and in the specific mechanisms through which trust built on performance rather than substance eventually collapses.
Holmes built trust through several mechanisms: the selection of prestigious validators (the board, the partnerships with Walgreens and Safeway, the press coverage), the control of information (the secrecy culture, the NDAs, the physical security of the laboratory), and the sustained performance of certainty and vision she delivered consistently across hundreds of investor meetings, press interviews, and board presentations. Each was a substitute for the one trust-building mechanism she couldn’t provide: demonstrated alignment between her claims and the underlying reality.
The collapse of trust in Theranos, when it came, was faster and more complete than the buildup. This is the asymmetry of trust that Carreyrou’s book illustrates vividly: the stock of credibility Holmes had accumulated over more than a decade dissolved within months of the first serious investigative journalism. The prestigious validators — the board members, the corporate partners, the investors — who had been the most visible endorsers of Theranos became, in the aftermath of the collapse, either embarrassed defenders or critics of the governance structures they’d been part of. The trust had been performance-dependent, and when the performance was exposed as a performance, the trust it had generated evaporated.
Worth considering the counterfactual: what would have happened if Holmes had been honest with her board and investors about the state of the technology in 2012 or 2013, when it was becoming clear the Edison device wasn’t going to achieve the capabilities she’d promised on the timeline she’d committed to? The company might have survived in a different form — as a conventional laboratory services company with a longer-term research program in diagnostic innovation. The shareholders would have suffered losses, and Holmes would have faced significant professional consequences. But the patients who received inaccurate medical results, the employees who were threatened and silenced, and Holmes herself would have been spared the consequences of a fraud that compounded over years into something that destroyed everything it touched.
Theranos and the Systemic Lessons for Healthcare Innovation
The Theranos story has specific implications for the way innovation in healthcare is funded, evaluated, and regulated that extend well beyond the specifics of one fraudulent company. Healthcare is a domain where the potential impact of genuine innovation is enormous and where the costs of fraudulent or premature claims about innovation are extraordinarily high. The combination of these two facts creates structural pressures that Theranos exploited — and that its story illuminates in ways that remain relevant to everyone building or funding healthcare technology.
The healthcare investor’s dilemma: the companies that succeed in transforming healthcare often do so by making claims that sound impossible to conventional industry practitioners. Every significant diagnostic and therapeutic innovation encountered some version of the Theranos pitch — “we can do something the existing technology cannot do, and we’re right while the skeptics are wrong.” Distinguishing genuinely transformative technologies from fraudulent ones is hard, and the cultural lesson of Silicon Valley — that the visionary is often right and the skeptic is often wrong — creates a strong prior against demanding the kind of validation that would have exposed Theranos early.
The appropriate response to this dilemma is not to become skeptical of all audacious healthcare claims — some of them are genuine, and overly conservative evaluation standards impose their own costs in delayed access to beneficial technology. It is to develop domain-specific protocols for validation that require evidence appropriate to the claims being made, that involve independent scientific evaluation rather than relying on the company’s own data, and that escalate the validation requirements in proportion to the patient safety implications of the technology.
Clinical laboratory testing is a domain with specific patient safety implications — incorrect results affect treatment decisions — and the validation standards for clinical tests exist precisely because incorrect results can harm patients. Holmes’s strategy of using legal structures to avoid those standards was not clever innovation; it was the deliberate circumvention of safeguards designed to protect the people who would ultimately rely on the technology. The lesson for healthcare innovation is that the patient safety framework is not optional infrastructure to be routed around — it is the foundation on which trust in healthcare technology is built, and its erosion has costs that extend far beyond any individual fraud.
“It’s only by saying no that you can concentrate on the things that are really important.” — Steve Jobs (a maxim Holmes invoked while doing precisely the opposite: saying yes to every claim regardless of whether it was true)
The lasting contribution of Bad Blood to healthcare innovation is not the specific legal outcomes — the criminal convictions of Holmes and Balwani — but the detailed case study it provides of how clinical validation requirements can be circumvented through a combination of legal structuring, regulatory avoidance, and the exploitation of institutional cultures that reward confidence over verification. The case study is valuable precisely because it is so specific: the mechanisms Theranos used, the validators it exploited, and the oversight gaps it navigated are all documented in sufficient detail to enable the people designing healthcare innovation policy to understand where the vulnerabilities were and what kinds of institutional safeguards would have closed them.
Related: Complex PTSD Summary
Related: The Seven Principles for Making Marriage Work Summary
Related: Breath by James Nestor Summary: Key Takeaways and What to Do Next
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map